Clinical trial
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung…
NCT00319969 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00319969 |
|---|---|
| Title | Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. |
| Official title | A Randomized Phase 2 Trial Comparing Amrubicin Versus Topotecan as Second-Line Treatment in Patients With Extensive Small Cell Lung Cancer Sensitive to First-Line Chemotherapy |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Amrubicin, Topotecan |
| Enrollment | 76 |
| Start date | Apr 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Apr 27, 2006 |
| Last update posted | Sep 30, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: